WO2018063876A1 - Systèmes d'administration transdermique et/ou topique comprenant du dichlorhydrate de cétirizine - Google Patents

Systèmes d'administration transdermique et/ou topique comprenant du dichlorhydrate de cétirizine Download PDF

Info

Publication number
WO2018063876A1
WO2018063876A1 PCT/US2017/052408 US2017052408W WO2018063876A1 WO 2018063876 A1 WO2018063876 A1 WO 2018063876A1 US 2017052408 W US2017052408 W US 2017052408W WO 2018063876 A1 WO2018063876 A1 WO 2018063876A1
Authority
WO
WIPO (PCT)
Prior art keywords
days
transdermal
amount
gel formulation
formulation
Prior art date
Application number
PCT/US2017/052408
Other languages
English (en)
Inventor
Fotios Plakogiannis
Tamanna LATHER
Marina BOROVINSKAYA
Nisarg MODI
Original Assignee
Alpha To Omega Pharmaceutical Consultants, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha To Omega Pharmaceutical Consultants, Inc. filed Critical Alpha To Omega Pharmaceutical Consultants, Inc.
Publication of WO2018063876A1 publication Critical patent/WO2018063876A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Definitions

  • the invention relates to in vitro transdermal delivery of cetirizine dihydrochloride (Synonym: cetirizine hydrochloride 19 ) for a period of up to, for example, 7 days from a semisolid transdermal formulation preferably transdermal gel formulation.
  • cetirizine dihydrochloride Synonym: cetirizine hydrochloride 19
  • invention suggest transdermal delivery of cetirizine dihydrochloride by topical application of transdermal gel formulation to skin and/or by incorporation of transdermal gel formulation into a transdermal delivery system particularly reservoir patch which can be topically applied to skin for the treatment and/or prevention and/or relief of symptoms associated with allergic rhinitis and/or urticaria and/or upper respiratory allergies wherein duration of topical application of transdermal gel is for up to one day and/or duration of topical application of reservoir patch can be selected from the group comprising for one day, two days, three days, four days, five days, six days, seven days. Topical application of reservoir patch to skin for more than one day can reduce the dosing frequency of cetirizine dihydrochloride.
  • Allergic rhinitis is caused by the reaction of the immune system to allergens. Symptoms of allergic rhinitis may develop when people inhale an allergen or consume a food to which they are allergic 3 . Symptoms of allergic rhinitis includes such as sneezing, watery eyes, runny nose, stuffy nose, itchy eyes, itchy mouth, itchy skin, fatigue 2 ' 3 , etc. Allergic rhinitis can be seasonal and perennial. In seasonal allergic rhinitis symptoms can appear in spring, summer and early fall. Allergens for seasonal allergic rhinitis are such as grass, trees and weeds pollen. In perennial allergic rhinitis symptoms are occurring throughout the year. Allergens for perennial allergic rhinitis are such as dander, dust mites, moid or cockroach, pet hair 2 , etc.
  • Urticaria occurs in more than 20% people worldwide at some point in their lifetime 4 ' 5 .
  • Urticaria or hives affects the skin and symptoms includes such as red or skin colored raised itchy bumps, blanching, welts 5 ' 6 .
  • Hives can vary in size and shape, appear and disappear anywhere on the body 5 ' 6 . Usually each hive disappear within 24 hours and does not leave scar or bruise.
  • Urticaria can be acute or chronic. Acute urticaria is short lived and last for few weeks. Urticaria is chronic or long term if symptoms appear daily for more than six weeks 5 ' 6 .
  • Hives can be triggered by factors such as pollen, some plants, some food, some medicines, bacterial or viral infections, physical stimuli, pet dander, blood transfusion, insect bites, latex 5 , etc.
  • Urticaria can also be idiopathic.
  • Cetirizine ((+/-)- [2-[4-[(4-chlorophenyl) phenylmethyl] -1 -piperazinyl] ethoxy] acetic acid), has the structure
  • Cetirizine hydrochloride can treat the symptoms of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. Zyrtec label states, "Cetirizine hydrochloride treats uncomplicated skin manifestations of chronic idiopathic urticaria and reduces the occurrence, duration and severity of hives and decreases pruritus.
  • Symptoms treated effectively includes nasal pruritus, sneezing, ocular pruritus, rhinorrhea, tearing, postnasal discharge, redness of the eyes.
  • Allergens for seasonal allergic rhinitis include for example ragweed, grass and tree pollens.
  • Allergens for perennial allergic rhinitis include for example animal dander, dust mites, molds" 1 .
  • cetirizine hydrochloride is administered once daily. Commercially cetirizine hydrochloride is available as syrup, tablet, orally disintegrating tablet, chewable tablet, capsule and ophthalmic solution or drops.
  • allergic rhinitis symptoms can be troublesome. Symptoms like nasal congestion, runny nose, sneezing, itching, watery eyes, fatigue can make the person irritable, tired, affect the sleep and work output 7 ' 9 .
  • a cross sectional study was conducted with 683 adult allergic rhinitis patients and reported for employed patients and student patient loss of productivity was around 21 %, and impact on daily activities was around 22% 8 . If left untreated allergic rhinitis symptoms can affect the quality and comfort of life. Similarly, chronic urticaria can also undermines the quality of life due to itching, raised bumps on the skin. Visible hives accompanied with itching on the skin can impact the social life and emotions of the patient 10 .
  • Symptoms of seasonal allergic rhinitis last from day to few weeks and for perennial allergic rhinitis symptoms can occur anytime throughout year. Similarly, urticaria can last up to a day to few weeks to six weeks and more.
  • cetirizine hydrochloride everyday till the rhinitis and urticaria goes way. This everyday drug administration can be inconvenient for the patients. Therefore, for the treatment and/or prevention of symptoms associated with allergic rhinitis and urticaria there is a requirement for a better drug delivery system which can decrease the dosing frequency.
  • the transdermal delivery of cetirizine dihydrochloride can reduce the frequency of drug administration.
  • transdermal drug delivery drug is delivered through the skin.
  • the transdermal formulation or transdermal delivery system is topically applied to the intact skin surface.
  • Drug is released from topically applied transdermal formulation or transdermal delivery system and delivered to systemic circulation through the intact skin via different routes such as intercellular routes, transcellular route, transappendageal route to attain pharmacologic effect.
  • Drug is continuously released and delivered to systemic circulation during the entire period of application of transdermal formulation or transdermal delivery system to skin.
  • transdermal delivery dosing frequency of drug administration can be reduced as drug can be delivered for the entire period of application of transdermal formulation or transdermal delivery system to skin wherein period of application is variable and can be for one day, two days, three days, four days, five days, six days, seven days or more.
  • Transdermal delivery of cetirizine dihydrochloride can overcome its current dosage administration of orally every day.
  • the Cetirizine dihydrochloride transdermal formulation or cetirizine dihydrochloride transdermal delivery system as set forth herein can be applied topically to skin and can deliver cetirizine dihydrochloride into systemic circulation during the entire period of its application wherein period of application can be selected from the group such as for one day, for two days, for three days, for four days, for five days, for six days, for seven days, or more. Therefore, transdermal delivery of cetirizine dihydrochloride can overcome every day dose regimen of oral delivery by continuously delivering the drug for longer time period.
  • Transdermal delivery of the drug can be stopped anytime (in any emergency, side effects, adverse effects) by removing the transdermal formulation or transdermal delivery system from the patient's skin.
  • cetirizine dihydrochloride transdermal delivery system of the invention can be applied and left on skin for a period of time, for example, selected from the group 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, or more.
  • the transdermal gel formulation of cetirizine dihydrochloride of the invention can be topically applied and left on the skin for up to one day.
  • Transdermal delivery of cetirizine dihydrochloride can provide convenient and patient friendly dosing regimen to patients with allergic rhinitis and chronic urticaria.
  • transdermal and topical drug delivery formulations or systems are applied to the patient's skin surface but there is a difference in both the drug delivery.
  • drug penetrates through the skin and reaches systemic circulation to have pharmacologic effect" . Therefore, in transdermal drug delivery drug plasma concentration is in therapeutic range.
  • topical drug delivery drug either does not or minimally penetrate through the skin and exert localized effect or exert effect at its site of application 1 1 . Therefore, there is insignificant drug plasma concentration.
  • Patent application US20120027876A1 discloses the treatment of dermatitis by topical application of formulation comprising one or more antihistamine, one or more polysaccharide and one or more group 1 , 2 or 13 metal hydroxides.
  • Topical formulations comprising antihistamine drugs such as diphenhydramine hydrochloride, loratadine, cetirizine hydrochloride.
  • a topical gel-type dispersion formulation comprising cetirizine hydrochloride is prepared by using equate children's allergy relief cetirizine hydrochloride oral medicine, equate max strength liquid antacid, xanthan gum powder and corn starch.
  • This patent application is about the topical treatment in which composition is applied to affected area with dermatitis which gives shield from external environment by leaving a light film. Furthermore, formulation decreases the span of rash by drying out the irritants.
  • Patent application US20140079791A1 discloses a transdermal composition, prepared by first coating the active pharmaceutical ingredient particles with highly volatile silicones or mixtures of highly volatile silicones and later dispersing the coated active pharmaceutical particles in a cream or gel base. Silicone compound evaporates after application of gel to skin surface. Example and method of preparation of cetirizine gel composition is disclosed. The patent application mentions about the cetirizine but does not teach or inform about the salt of cetirizine such as cetirizine dihydrochloride.
  • US Patent number 6790847B2 discloses antihistamine gel formulations for topical application to the skin.
  • the patent states that the "object of the invention is to provide a fast and locally acting pharmaceutical form of the preferred antihistamines cetirizine and loratadine for the treatment of disorders or diseases of the skin resulting from excessive release of histamine which permits a rapid onset of the effect".
  • cetirizine hydrochloride gel formulations are disclosed.
  • One of the cetirizine hydrochloride gel formulation was applied to the skin of 20 volunteers and relieved sunburn, redness and itching caused by insect bites or sunburn.
  • US Patent number 6258816B l discloses "sulfonanilide NSAIDs e.g. Nimesulide and thereof when combined with cetirizine forms an excellent synergistic antileukotriene, antihistaminic, anti-allergy and anti-inflammatory composition".
  • NSAIDs e.g. Nimesulide and thereof when combined with cetirizine forms an excellent synergistic antileukotriene, antihistaminic, anti-allergy and anti-inflammatory composition.
  • Examples of different dosage form are disclosed such as tablets, topical gel, transdermal gel, capsules, sustained release bilayer tablets, metered dose inhaler, injection.
  • Topical gel example contains both nimesulide and cetirizine (suitable pharmaceutical form).
  • US patent number 6277387B 1 relates to the addition of a histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist to compositions wherein compositions are cosmetic, pharmaceutical or dermatological.
  • the patent relates to the treatment of sensitive skin, irritable skin, inhibiting manifestations of irritable skin and preventing or decreasing the irritant side effects of dermatological, cosmetic or pharmaceutical active agents.
  • cetirizine is incorporated in very small percentage that is, make up removal lotion for the face contains 0.001% cetirizine, antiwrinkle skin care cream for the face contains 0.15% cetirizine, pain relief gel contains 0.03% cetirizine.
  • US Patent number 5627183A discloses "Methods are disclosed utilizing optically pure (+) cetirizine for the treatment of urticaria in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine". Patent talks about different routes of administration for example parenteral, oral, rectal, transdermal and like forms of administration. Only oral formulation examples of capsules and tablets are disclosed.
  • references as set forth above disclose about once a day delivery of cetirizine dihydrochloride through topical and/or transdermal route.
  • the invention as disclosed herein can deliver cetirizine dihydrochloride to the systematic circulation through patch technology for up to 7 days or more. This invention will help to improve patient compliance by reducing dosing frequency and also deliver uniform amount of cetirizine dihydrochloride to the patients for up to 7 days or more.
  • the invention provides continuous in vitro transdermal delivery of cetirizine dihydrochloride from transdermal gel formulation for 7 days.
  • In another aspect invention provides the method for reducing the dosing frequency of cetirizine dihydrochloride.
  • transdermal formulation for transdermal delivery of cetirizine dihydrochloride semisolid transdermal formulation is a transdermal gel formulation.
  • transdermal formulation is composed of cetirizine dihydrochloride and carrier system.
  • carrier system is composed of excipients selected from the group of solvents, penetration enhancers, gelling agents or polymers, pH adjusting agents either alone or in combinations thereof.
  • transdermal semisolid formulation comprises cetirizine dihydrochloride in an amount between 2%- 30% w/w and carrier system in an amount between 70%- 98% w/w. More preferably, cetirizine dihydrochloride in an amount between 3%- 20%w/w and carrier system in an amount between 80%- 97% w/w. Most preferably, cetirizine dihydrochloride in an amount between 6% - 15% w/w and carrier system in an amount between 85%- 94% w/w.
  • transdermal gel formulation comprises cetirizine dihydrochloride in an amount between 2%- 30% w/w and carrier system in an amount between 70%- 98% w/w. More preferably, cetirizine dihydrochloride in an amount between 3%- 20%w/w and carrier system in an amount between 80%- 97%> w/w. Most preferably, cetirizine dihydrochloride in an amount between 6% - 15% w/w and carrier system in an amount between 85%- 94% w/w.
  • a transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 0.1%- 40%w/w, dimethyl sulfoxide in an amount between 1 %- 80%w/w, hexylene glycol in an amount between 1%- 80%w/w, diethylene glycol monoethyl ether (Transcutol P) in an amount between 1 %- 80%w/w, lactic acid in an amount between 1%- 80%w/w, oleyl alcohol (kollicream OA) in an amount between 0.5%- 50%w/w, ethanol in an amount between 1 %- 80%w/w, glycerin in an amount between 0.5%- 70%w/w , propylene glycol monolaurate type II (lauroglycol 90) in an amount between 0.5%- 70%w/w, water in an amount between 0.5%- 85%w/w, sodium hydroxide 50% w/w in an amount between 0.05%- 30%w/w , hydroxypropyl cellulose
  • transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 0.1 %- 40%w/w, dimethyl sulfoxide in an amount between 5%- 60% w/w, hexylene glycol in an amount between 1%- 50%w/w, diethylene glycol monoethyl ether (Transcutol P) in an amount between 2% - 50%w/w, lactic acid in an amount between 1 %- 30%w/w , oleyl alcohol (kollicream OA) in an amount between 1 %- 30% w/w, ethanol in an amount between 1 %- 50%w/w, glycerin in an amount between 1%- 30%w/w , propylene glycol monolaurate type II (lauroglycol 90) in an amount between 1 %- 30% w/w, water in an amount between 1%- 60%w/w, sodium hydroxide 50% w/w in an amount between 0.5%- 15%w/w, hydroxypropyl cellulose (K
  • semisolid transdermal formulation comprising cetirizine dihydrochloride and carrier system can be added to transdermal delivery system wherein, transdermal delivery system is a reservoir system.
  • semisolid transdermal formulation is transdermal gel formulation comprising cetirizine dihydrochloride and carrier system which can be added to transdermal delivery system wherein, transdermal delivery system is a reservoir system.
  • Method of treatment and/or prevention and/or relief of symptoms associated with allergic rhinitis and/or urticaria includes either the topical application of transdermal formulation or topical application of reservoir system containing transdermal formulation to the skin wherein duration of topical application of transdermal formulation is for up to 1 day and, wherein duration of topical application of reservoir patch containing transdermal formulation is selected from the group for one day, for two days, for three days, for four days, for five days, for six days, for seven days.
  • method of treatment and/or prevention and/or relief of symptoms of allergic rhinitis and/or urticaria includes either the topical application of transdermal gel formulation or topical application of reservoir system incorporated with transdermal gel formulation to the skin wherein duration of topical application of transdermal gel is for up to 1 day and, wherein duration of topical application of reservoir patch containing transdermal gel formulation is selected from the group for one day, for two days, for three days, for four days, for five days, for six days, for seven days thereby reducing the dosing frequency.
  • the invention provides a semisolid transdermal formulation for transdermal delivery of cetirizine dihydrochloride.
  • the invention provides a semisolid transdermal formulation for transdermal delivery of cetirizine dihydrochloride wherein the formulation is a transdermal gel formulation.
  • the invention provides a transdermal gel formulation comprising cetirizine dihydrochloride and a carrier system.
  • the invention provides a transdermal gel formulation wherein the carrier system comprises excipients selected from the group consisting of solvents, penetration enhancers, gelling agents, thickening agents, polymers, pH adjusting agents, stabilizing agents, skin irritation reducing agents either alone and combinations thereof.
  • the invention provides a transdermal gel formulation wherein the carrier system comprises excipients selected from the group consisting of solvents, penetration enhancers, gelling agents, polymers, pH adjusting agents, and combinations thereof.
  • the invention provides a transdermal gel formulation wherein the solvent is present and selected from the group consisting of cosolvents, sulfoxide, alcohol, polyhydric alcohol, glycol, acid, glycol ether, water, polar solvents, semi polar solvents, nonpolar solvents, pyrrolidone, dimethylisosorbide, and combinations thereof.
  • the invention provides a transdermal gel formulation wherein the penetration enhancer is present and is selected from the group consisting of fatty alcohol, propylene glycol mono-and diesters of fats and fatty acids, solubilizers, surfactants, fatty acid, esters, terpene and terpenoids, sulfoxide, alcohol, amide, triglycerides, and combinations thereof.
  • the invention provides a transdermal gel formulation wherein the penetration enhancer is present and is selected from the group consisting of fatty alcohol, propylene glycol mono- and diesters of fats and fatty acids (such as propylene glycol monolaurate type II), esters, terpene and terpenoids, and combinations thereof.
  • the invention provides a transdermal gel formulation wherein the gelling agents is present and is selected from the group consisting of cellulose, cellulose derivatives, , carboxyvinyl polymers, natural polymers and derivatives, synthetic polymers and derivatives, semisynthetic polymers and derivatives, polysaccharides and derivatives, water swellable, organic solvent swellable polymers, and combinations thereof.
  • the invention provides a transdermal gel formulation wherein the pH adjusting agent is present and is selected from the group consisting of acids, bases, buffer, and combinations thereof.
  • the invention provides a transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 1 %- 40% w/w and carrier system in an amount between 99%-60% w/w.
  • the invention provides a transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 3%- 30% w/w and carrier system in an amount between 97%-70% w/w.
  • the invention provides a transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 5%- 20% w/w and carrier system in an amount between 95%-80% w/w.
  • the invention provides a transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 6%- 18%o w/w and carrier system in an amount between 94%>-82%> w/w.
  • the invention provides a transdermal gel formulation comprising: cetirizine dihydrochloride in an amount between 6%>- 18%w/w, dimethyl sulfoxide in an amount between 5%>- 60% w/w, hexylene glycol in an amount between 1%- 50%)w/w, diethylene glycol monoethyl ether in an amount between 2% - 50%w/w, lactic acid in an amount between 1 %- 30%w/w, oleyl alcohol) in an amount between ⁇ %- 30%) w/w, ethanol in an amount between 1%>- 50% w/w, glycerin in an amount between l %o- 30%ow/w, propylene glycol monolaurate type II in an amount between 1%)- 30%) w/w, water in an amount between l %o- 60%>w/w, sodium hydroxide 50% w/w in an amount between 0.5%>- 15%ow/w, and hydroxypropyl cellulose (Klucel HF
  • the invention provides a semisolid transdermal formulation wherein the duration of transdermal delivery of cetirizine dihydrochloride is selected from the group of l day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, and more than 7 days.
  • the invention provides a semisolid transdermal formulation wherein the duration of transdermal delivery of cetirizine dihydrochloride is 7 days.
  • the invention provides a semisolid transdermal formulation wherein the duration of transdermal delivery of cetirizine dihydrochloride is 3 days.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of one or more symptoms of allergic rhinitis comprising topical application of a transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of one or more symptoms of allergic rhinitis comprising topical application of a reservoir patch comprising a transdermal gel formulation of the invention to a patient in need thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of skin manifestations and/or one or more symptoms of urticaria comprising topical application of a transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of skin manifestations and/or one or more symptoms of urticaria comprising topical application of a reservoir patch comprising a transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of one or more symptoms of allergies comprising topical application of a transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of one or more symptoms of allergies comprising topical application of a reservoir patch comprising the transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of one or more symptoms of upper respiratory allergies comprising topical application of the transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction and/or relief of one or more of symptoms of upper respiratory allergies comprising topical application of a reservoir patch comprising the transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction of one or more symptoms due to release of extra histamines in the body of a patient comprising topical application of the transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of treatment and/or prevention and/or reduction of one or more symptoms due to release of extra histamines in the body of a patient comprising topical application of a reservoir patch comprising the transdermal gel formulation of the invention to a patient in need of thereof.
  • the invention provides a method of the invention wherein the duration of topical application is for one day or up to one day.
  • the invention provides a method of the invention wherein the duration of topical application is selected from the group consisting of one day, for two days, for three days, for four days, for five days, for six days, and for seven days.
  • the invention provides a method of the invention wherein the duration of topical application is for one day or up to one day.
  • the invention provides a method of the invention wherein the duration of topical application is selected from the group consisting of one day, for two days, for three days, for four days, for five days, for six days, and for seven days.
  • the invention provides a method of the invention wherein the duration of topical application is for one day or up to one day.
  • the invention provides a method of the invention wherein the duration of topical application is selected from the group consisting of for one day, for two days, for three days, for four days, for five days, for six days, and for seven days.
  • the invention provides a method of the invention wherein the duration of topical application is for one day or up to one day.
  • the invention provides a method of the invention wherein the duration of topical application is selected from the group consisting of for one day, for two days, for three days, for four days, for five days, for six days, and for seven days.
  • the invention provides a method of the invention wherein the duration of topical application is for one day or up to one day.
  • the invention provides a method of the invention wherein the duration of topical application is selected from the group consisting of for one day, for two days, for three days, for four days, for five days, for six days, and for seven days.
  • Figure 1 is is a graph of Flux ⁇ g/cm 2 /hr) VS Time (hour), presenting in vitro transdermal delivery of cetirizine dihydrochloride through human cadaver skin continuously for seven days from transdermal gel formulation.
  • Cetirizine dihydrochloride refers to all pharmaceutically acceptable forms of cetirizine either alone or in combinations thereof, for example in following forms but not limited to such as salt or racemic form of salt or base or racemic form of base, solid solution or isomer or crystalline or co crystalline or amorphous or prodrug or metabolites or derivatives or analogs.
  • active substance or active agent refers to Cetirizine dihydrochloride.
  • cetirizine dihydrochloride cetirizine hydrochloride
  • penetration enhancers and permeation enhancers are used interchangeably.
  • the phrase "pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government, or listed in the U.S. Pharmacopeia, European Pharmacopeia, or other generally recognized pharmacopeia for use in animals, and more particularly, in humans.
  • derivative or “derivatized” as used herein includes chemical modification of a compound of the invention, or pharmaceutically acceptable salts thereof or mixtures thereof. That is, a “derivative” may be a functional equivalent of a compound of the invention, which is capable of inducing the improved pharmacological functional activity in a given subject. Illustrative of such chemical modifications would be replacement of hydrogen by a halo group, an alkyl group, an acyl group or an amino group.
  • the term “pharmaceutically acceptable salts” includes acid addition salts or addition salts of free bases.
  • pharmaceutically acceptable salts" of a compound of the invention is also meant to include within its scope all the possible isomers , racemic form and their mixtures, and any pharmaceutically acceptable metabolite, bioprecursor and/or pro-drug, such as, for example, a compound which has a structural formula different from the one of the compounds of the invention, and yet is directly or indirectly converted in vivo into a compound of the invention, upon administration to a subject, such as a mammal, particularly a human being.
  • the compound may be in the form of a pharmaceutically acceptable salt, such as an acid addition salt or a base salt, or a solvate thereof, including a hydrate thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and pamoate salts.
  • Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.
  • formulation and composition are used interchangeably.
  • reservoir patch and reservoir system are used interchangeably.
  • semisolid includes without any limitation such as gels, creams, ointments, lotion, emulsion, suspension, paste, balms, wherein gels are preferred.
  • solvents for example, solvents, penetration enhancers, gelling agents, polymers, thickening agents, pH adjusting agents, suspending agents, stabilizing agents, surfactants, emulsifying agents, skin irritation reducing agents, humectants, emollients alone or in combinations thereof can be used in semisolid formulations.
  • ⁇ g stands for microgram
  • cm stands for centimeter
  • hr stands for hour
  • g stands for gram
  • hrs stands for hours
  • compositions or formulations are weight by weight percent.
  • Topical administration includes administration to the skin or mucosa for transdermal delivery. Administration of the compositions according to the present invention may be via any common topical route so long as the target tissue is available via that route. This includes direct topical administration to an affect area of, for example, the skin or mucosal surface or scalp or genital area.
  • topical application refers to application to skin.
  • transdermal refers to delivery, administration or application of a drug by means of direct contact with skin or mucosa. Such delivery, administration or application is also known as dermal, percutaneous, transmucosal and buccal. As used herein, “dermal” includes skin and mucosa, which includes oral, buccal, nasal, rectal and vaginal mucosa.
  • transdermal delivery system refers to transdermal patch, patch, reservoir patch, and systems which can be topically applied to skin, patches known to those skilled in the art, comprising a transdermal formulation according to the invention.
  • transdermal drug delivery system refers to a system (e.g., a device) comprising a formulation that releases drug upon application to the skin.
  • the transdermal drug delivery system is a substantially nonaqueous, solid form, capable of conforming to the surface with which it comes into contact, and capable of maintaining such contact so as to facilitate topical application without adverse physiological response, and without being appreciably decomposed by aqueous contact during topical application to a subject.
  • Many such systems are known in the art and commercially available, such as transdermal drug delivery patches.
  • transdermal drug delivery systems are classified into one of two categories: matrix-type systems and reservoir-type systems.
  • a transdermal drug delivery system may be packaged or provided in a package, such as a pouchstock material used in the prior art for transdermal drug delivery systems in general.
  • a pouchstock material used in the prior art for transdermal drug delivery systems in general.
  • DuPont's SURLYN® can be used in a pouchstock material.
  • a pouchstock comprising a coextruded ethylene acrylic acid/low- density polyethylene (EAA/LDPE) material, or BAREX® from INEOS (acrylonitrile-methyl acrylate) may be used.
  • allergic rhinitis refers to seasonal allergic rhinitis and/or perennial allergic rhinitis.
  • urticaria refers to acute urticaria and/or chronic urticaria and/or chronic idiopathic urticaria.
  • the term “subject” and “patient” are used interchangeably.
  • the term “patient” refers to an animal, preferably a mammal such as a non- primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., monkey and human), and most preferably a human.
  • the subject is a non-human animal such as a farm animal (e.g., a horse, pig, or cow) or a pet (e.g., a dog or cat).
  • the subject is an elderly human.
  • the subject is a human adult.
  • the subject is a human child.
  • the subject is a human infant.
  • the term “agent” refers to any molecule, compound, methodology and/or substance for use in the prevention, treatment, management of a disease or disease symptoms or condition.
  • the term “effective amount” refers to the amount of a therapy that is sufficient to result in the prevention of the development, recurrence, or onset of a disease or condition, and one or more symptoms thereof, to enhance or improve the prophylactic effect(s) of another therapy, reduce the severity, the duration of a disease or condition, ameliorate one or more symptoms of a disease or condition, prevent the advancement of a disease or condition, cause regression of a disease or condition, and/or enhance or improve the therapeutic effect(s) of another therapy.
  • the terms “therapies” and “therapy” can refer to any method(s), composition(s), and/or agent(s) that can be used in the prevention, treatment and/or management of a disease or condition, or one or more symptoms thereof.
  • the terms “therapy” and “therapies” refer to small molecule therapy.
  • the terms “treat,” “treatment,” and “treating” in the context of the administration of a therapy to a subject refer to the reduction or inhibition of the progression and/or duration of a disease or condition, the reduction or amelioration of the severity of a disease or condition, and/or the amelioration of one or more symptoms thereof .
  • the terms "prevent,” “preventing” and/or “prevention” in the context of the administration of a therapy to a subject refer to the prevention or inhibition of the recurrence, onset, and/or development of a disease or condition, or a symptom thereof in a subject resulting from the administration of a therapy (e.g., a prophylactic or therapeutic agent), or a combination of therapies (e.g., a combination of prophylactic or therapeutic agents).
  • a therapy e.g., a prophylactic or therapeutic agent
  • a combination of therapies e.g., a combination of prophylactic or therapeutic agents
  • the invention provides a semisolid transdermal formulation for transdermal delivery of cetirizine dihydrochloride.
  • the semisolid transdermal formulation of cetirizine dihydrochloride is a transdermal gel.
  • transdermal gel formulation of the invention gives continuous in vitro transdermal delivery of cetirizine dihydrochloride for a duration of 7 days.
  • the transdermal gel formulation of the invention can be added into a transdermal delivery system, wherein transdermal delivery system is a reservoir patch.
  • invention provides method for reducing dosing frequency of cetirizine dihydrochloride.
  • Carrier system plays an important role in semisolid transdermal formulation.
  • the carrier system can have multiple functions in the formulation without any limitation such as it determines drug solubility, governs permeation of the drug, influence the release rate of drug, determines formulation stability, etc.
  • For a good transdermal formulation carrier system composition is highly important. To get the required transdermal delivery of drug appropriate selection, combination and concentration of carrier system excipients are very important.
  • the semisolid transdermal formulation comprises cetirizine dihydrochloride and a carrier system.
  • cetirizine dihydrochloride can be dissolved and/or suspended in the carrier system.
  • carrier system is comprised of excipients selected from the group of components such as but not limited to solvents, penetration enhancers, pH adjusting agents, polymers or gelling agents or thickening agents, stabilizing agents either alone or in combinations thereof.
  • carrier system is comprised of excipients selected from the group of components such as solvents, penetration enhancers, pH adjusting agents, gelling agents or polymers alone or in combinations thereof.
  • preferred semisolid transdermal formulation is a transdermal gel formulation.
  • semisolid transdermal formulation comprises cetirizine dihydrochloride in an amount between 1%- 49% w/w and carrier system in an amount between 51 %- 99% w/w.
  • cetirizine dihydrochloride in an amount between 2%- 30% w/w and carrier system in an amount between 70%- 98% w/w.
  • cetirizine dihydrochloride in an amount between 3%- 20%w/w and carrier system in an amount between 80%- 97% w/w.
  • cetirizine dihydrochloride in an amount between 6% - 15% w/w and carrier system in an amount between 85%- 94% w/w.
  • semisolid transdermal formulation is a transdermal gel formulation and comprises cetirizine dihydrochloride in an amount between 1%- 49% w/w and carrier system in an amount between 51%- 99% w/w.
  • cetirizine dihydrochloride in an amount between 2%- 30% w/w and carrier system in an amount between 70%- 98% w/w.
  • cetirizine dihydrochloride in an amount between 3%- 20%w/w and carrier system in an amount between 80%- 97% w/w.
  • cetirizine dihydrochloride in an amount between 6% - 15% w/w and carrier system in an amount between 85%- 94% w/w.
  • cetirizine dihydrochloride is present in the formulation in an amount between 1 %- 49% w/w.
  • cetirizine dihydrochloride is present in the formulation in an amount between 2%- 30% w/w. More preferably, cetirizine dihydrochloride is present in the formulation in an amount between 3%- 20%w/w. More preferably, cetirizine dihydrochloride is present in the formulation in an amount between 5%- 20%w/w. Most preferably, cetirizine dihydrochloride is present in the formulation in an amount between 6% - 15% w/w.
  • Solvents solubilize drug in the formulation. Required amount of drug cannot be added to the formulation if solubility of the drug is low in the solvent system which may result into failure of adequate transdermal delivery. At the same time if the solubility of drug is too high in the formulation, drug may not leave the formulation. Therefore, selection of solvent system having optimum drug solubility is very significant.
  • cosolvents may be added in the formulation which further helps to achieve the drug solubility. If required, solvents and cosolvents are also added to make up the weight of the formulations. Depending on the physicochemical properties of drug, at times there are limited solvents which can solubilize the drug.
  • excipients of solvents and cosolvents known to those skilled in the art are selected from the group such as but not limited to sulfoxide (such as but not limited to decylmethylsulfoxide, dimethyl sulfoxide, etc.), glycol ethers (such as but not limited to ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, etc.), acids (such as but not limited to ascorbic acid, levulinic acid, alginic acid, lactic acid, adipic acid, etc.), polyhydric alcohols (such as but not limited to glycerin, sorbitol, mannitol, etc.), pyrrolidone (such as but not limited to N-methyl 2-pyrrolidone, etc), glycols (such as but not limited to propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol, polyethylene glycol, polypropylene glycol, etc.), volatile
  • solvents are dimethyl sulfoxide, diethylene glycol monoethyl ether, lactic acid, glycerin, propylene glycol, hexylene glycol, dipropylene glycol, polyethylene glycol, ethanol, water, dimethylisosorbide.
  • Penetration enhancers are pharmacologically inactive chemicals. Their main function is to interact with the skin and increases the drug permeation or flux. Although lot of penetration enhancers are commercially available but there are very few penetration enhancers which facilitates or increases the permeation of a particular drug. For example, penetration enhancer for drug A may not act as penetration enhancer for drug B.
  • penetration enhancer may work as an enhancer with excipient combination of carrier system A and may not achieve its full effect with excipients combination carrier system B.
  • the invention may comprise excipients which are penetration enhancers known to those skilled in the art are selected from the group such as but not limited to fatty acids (such as but not limited to butyric acid, valeric acid, caprylic acid, capric acid, oleic acid, lauric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, etc.), fatty alcohol (such as but not limited to butyl alcohol, cetyl alcohol, myristyl alcohol, oleyl alcohol, stearyl alcohol, lauryl alcohol, etc.), glycol (such as but not limited to propylene glycol, polyethylene glycol, etc.), terpene and terpinoids (such as but not limited to limonene, terpineol, carvone, nerolidol, thymol, cineole
  • Gelling agents, thickening agents, and/or polymers may impart viscosity to the formulation. Viscosity gives body to the formulation and affects the release of the drug from the formulation. Generally due to viscosity, release of drug from the gel is always lower than from the solution.
  • excipients of gelling agents or thickening agents or polymers known to those skilled in the art are selected from the group such as but not limited to natural polymers, semisynthetic polymers, synthetic polymers, cellulose and its derivatives (such as but not limited to hydroxypropyl methyl cellulose, methyl cellulose, methylhydoxyethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, etc.), natural polymers, polysaccharides and its derivatives (such as but not limited to acacia, chitosan, agar, xanthum gum, alginic acid and derivatives, tragacanth, potassium or sodium carrageenan, guar gum, cassia tora, collagen, pectin, gelatin, gellum gum, gum copal, resin, starch, etc.), carboxyvinyl polymers or carbomers (such as but not limited to carbopol 9
  • pH adjusting agents known to those skilled in the art are selected from the group such as but not limited to base and its derivatives (such as but not limited to triethylamine, sodium hydroxide, ammonium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, etc.), acids and its derivatives (such as but not limited to acetic acid, ascorbic acid, hydrochloric acid, citric acid, fumaric acid, phosphoric acid, carboxylic acids, etc.), pH stabilizers, buffers (such as but not limited to phosphate buffer, citrate buffer, acetate buffer, etc.) either alone or in combinations thereof.
  • the preferable transdermal formulation of the invention comprises cetirizine dihydrochloride, solvents, penetration enhancers, gelling agents or polymers, pH adjusting agents.
  • Stabilizing agents known to those skilled in the art includes such as but not limited to complexing agents, antioxidants, oxidizing agents, chelating agents, preservatives, and excipients which helps to get stable formulation (such as but not limited to butylated hydroxyanisole, butylated hydroxytoulene, sodium metabisulfite, ascorbic acid, boric acid, citric acid, sorbic acid, ascorbyl palmitate, vitamin E, EDTA, benzyl alcohol, sodium benzoate, propylparaben, methylparaben, phenol, chlorocresol, etc.), surfactants and emulsifying agents (such as but not limited to nonionic surfactants, amphoteric surfactants, anionic surfactants, cationic surfactants, sodium lauryl sulfate, tween, span, tween 20, tween 40, tween 80, span 20, span 40, span 80, peg 400 monooleate, linoleoy
  • excipients While the disclosure has mentioned excipients herein, this is not meant to be limiting, and other suitable excipients for the transdermal formulation are mentioned in, for example, the "Handbook of Pharmaceutical Excipients, Sixth Edition,” published by the Pharmaceutical Press and the American Pharmacists Association, London, USA and “Remington's the science and practice of pharmacy, 21 st edition", published by the Wolter's Kluwer Company, PA, and penetration or permeation enhancers are set forth in "Percutaneous Penetration Enhancers” (Eric W. Smith, Howard I. Maibach, 2005. November, CRC press), and are also within the scope of the invention.
  • the invention provides transdermal gel formulation comprising cetirizine dihydrochloride and carrier system wherein components of carrier system are selected from the group such as solvents, penetration enhancers, gelling agents or polymers, pH adjusting agents either alone or in combinations thereof.
  • cetirizine dihydrochloride is present in an amount between 1 %- 49% w/w and carrier system is present in an amount between 51%-99% w/w.
  • cetirizine dihydrochloride is present in an amount between 2%- 30% w/w and carrier system is present in an amount between 70%- 98% w/w.
  • cetirizine dihydrochloride is present in an amount between 3%- 20%w/w and carrier system is present in an amount between 80%- 97% w/w. Most preferably, cetirizine dihydrochloride is present in an amount between 6% - 15% w/w and carrier system is present in an amount between 85%- 94% w/w.
  • the invention provides an exemplary transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 1 %- 40%w/w, dimethyl sulfoxide in an amount between 1%- 80%w/w, hexylene glycol in an amount between 1%- 80%w/w, diethylene glycol monoethyl ether (Transcutol P) in an amount between 1 %- 80%w/w, lactic acid in an amount between 1%- 80%w/w, oleyl alcohol (kollicream OA) in an amount between 0.5%- 50%w/w, ethanol in an amount between 1%- 80%w/w, glycerin in an amount between 0.5%- 70%w/w , propylene glycol monolaurate type II (lauroglycol 90) in an amount between 0.5%- 70%w/w, water in an amount between 0.5%- 85%w/w, sodium hydroxide 50% w/w in an amount between 0.05%- 30%w/w , hydroxypropyl
  • cetirizine dihydrochloride in an amount between 3%- 20%w/w, dimethyl sulfoxide in an amount between 5%- 60% w/w, hexylene glycol in an amount between 2%-50%w/w, diethylene glycol monoethyl ether (Transcutol P) in an amount between 2% - 50%w/w, lactic acid in an amount between 2%- 30%w/w , oleyl alcohol (kollicream OA) in an amount between 1 %- 30% w/w, ethanol in an amount between 2%- 50%w/w, glycerin in an amount between 1%- 30%w/w , propylene glycol monolaurate type II (lauroglycol 90) in an amount between 1%- 30%» w/w, water in an amount between 2%- 60%w/w, sodium hydroxide 50% w/w in an amount between 0.5%- 15%w/w, hydroxypropyl cellulose (Klucel HF) in an amount between
  • transdermal gel formulation comprising cetirizine dihydrochloride in an amount between 0.1%- 40%w/w, dimethyl sulfoxide in an amount between 5%- 60% w/w, hexylene glycol in an amount between l %-50%w/w, diethylene glycol monoethyl ether (Transcutol P) in an amount between 2% - 50%w/w, lactic acid in an amount between 1 %- 30%w/w , oleyl alcohol (kollicream OA) in an amount between 1%- 30% w/w, ethanol in an amount between 1%- 50%w/w, glycerin in an amount between 1 %- 30%w/w , propylene glycol monolaurate type II (lauroglycol 90) in an amount between 1%- 30% w/w, water in an amount between 1 %- 60%w/w, sodium hydroxide 50% w/w in an amount between 0.5%- 1 5%w/w, hydroxypropyl cellulose (Transcut
  • a beaker accurately weigh the required quantities of dimethyl sulfoxide, hexylene glycol, diethylene glycol monoethyl ether (Transcutol P), lactic acid, oleyl alcohol (kollicream OA), ethanol, glycerin, propylene glycol monolaurate type II (lauroglycol 90), water. Mix all the weighed ingredients on the magnetic stirrer to obtain clear solution. Add accurately weighed cetirizine dihydrochloride to the solution and stir on magnetic stirrer until fully dissolve. Now add accurately weighed sodium hydroxide 50%w/w to the drug solution and mix it by stirring on the magnetic stirrer. Slowly add the accurately weighed gelling agent hydroxypropyl cellulose (klucel HF) while stirring on the magnetic stirrer and stir overnight on magnetic stirrer to get clear gel.
  • Dimethyl sulfoxide hexylene glycol, diethylene glycol monoethyl ether (Transcutol P), lactic acid, oleyl alcohol (k
  • Example 4 is an exemplary optimized formulation and Example 1 -3 are representative graphs indicating that by small changes in the concentration of the ingredients or changes in the ingredients changes in the individual flux are observed; however, all release the active for 7 days. This suggests that by using formulation 045 ingredients, the steady state profile of cetirizine dihydrochloride can be achieved.
  • Figure 1 shows the in vitro transdermal flux of cetirizine dihydrochloride from formulation through human cadaver skin for a continuous period of 7 days.
  • transdermal gel formulation of the invention can be added into a transdermal delivery system wherein transdermal delivery system is a reservoir patch.
  • transdermal delivery system is a reservoir patch.
  • components of reservoir patch well known in the art includes backing layer, release membrane, adhesive, protective liner or release liner.
  • Outermost layer of the reservoir patch is backing layer.
  • backing layer and release membrane are sealed to form a cavity in which formulation is filled and act as a reservoir.
  • release membrane is the adhesive.
  • adhesive is the protective liner which is removed prior to application of reservoir patch to skin.
  • reservoir patch Upon application of reservoir patch adhesive and/or release membrane is in the contact with the skin. Reservoir patch is sealed or prepared in a way to avoid the formulation leakage during storage or in use. It is well known to those skilled in the art that there are other ways to attach the reservoir patch to the skin such as by adhesive overlays, in- line adhesive layer, other fastening means such as elastic armbands, belts, tapes, buckles. Although the well-known design of reservoir patch in the art has been described but it is well known to those skilled in the art that there can be several modifications in the design of the reservoir patch such as active substance and/or other excipients can be mixed with the adhesive and this adhesive can be coated on the release membrane. The modifications in the design of reservoir patch are also within the scope of this patent application without departing from the spirit and scope thereof.
  • Backing layer may be thin, flexible, robust and should not react with active substance or formulation excipients. It keeps the formulation safe during storage and use, it prevents the loss of active substance or drug substance and excipients from the formulation, provides appropriate occlusitivity.
  • Backing film known to those skilled in the art includes such as but not limited to films of ethylene/vinyl acetate copolymers, polyester, polyurethane, polyethylene, polyvinyl chloride, vinyl acetate resins, aluminized films, metal foils, non-woven fabric etc.
  • backing layer includes 3M ScotchpakTM 1012 backing polyester film laminate, 3M ScotchpakTM 9723 backing tan polyester film laminate, 3M ScotchpakTM 9730 backing tan polyester film laminate, 3M ScotchpakTM 9733 backing polyester film laminate, 3M ScotchpakTM 9754 polyester film, 3M ScotchpakTM 9757 polyester film, 3M ScotchpakTM 9758 polyester film, 3M CoTranTM 9700 backing melt-blown polyurethane nonwoven backing, 3M CoTranTM 9701 backing polyurethane monolayer film, 3M CoTranTM 9719 backing polyethylene monolayer film, 3M CoTranTM 9722 backing polyethylene monolayer film, DOW BLF 2050 backing layer, etc.
  • Release membrane allows the diffusion of the drug and other formulation components from formulation reservoir to the skin.
  • release membrane are permeable microporous or rate controlling membrane. Rate controlling release membrane controls the rate of diffusion of drug.
  • microporous release membrane includes such as microporous polypropylene membrane, microporous polyethylene membrane, etc.
  • rate controlling release membrane includes such as ethylene vinyl acetate copolymer membrane, etc.
  • release membranes which are well known to those skilled in the art also within the scope of this patent application.
  • adhesives or adhesive layer helps the transdermal system to fix or adhere to the skin firmly during its period of use.
  • Pressure sensitive adhesives known to those skilled in the art includes such as but not limited to silicone polymers, acrylic polymers, acrylic copolymers, rubber based adhesives, crosslinked polymers such as styrene- butadiene copolymers, polyisobutylene, polybutylene, hot melt adhesive etc.
  • pressure sensitive adhesive includes amine compatible BIO PSA- 7-4202, amine compatible BIO-PSA 7- 4301 , BIO-PSA hot melt 7-4560, BIO PSA- 7-4602, BIO PSA- 7-4601 , DURO-TAK 387-2054, DURO- TAK 387-2156, DURO-TAK 87-9301 , DURO-TAK 387-2287, DURO-TAK 87- 235A, polyisobutylene medium molecular weight, polyisobutylene low molecular weight, polyisobutylene 55000 mw, polyisobutylene 2300 mw, polyisobutylene 35000 mw, polyisobutylene 1 100000, acrylic adhesive 788, etc.
  • excipients are such as mineral oil.
  • other adhesives and excipients which are well known to those skilled in the art also within the scope of this patent application
  • Protective liner or release liners are located next to release membrane or adhesives. Protective liners protect the adhesive, release membrane or formulation during storage. Protective liner is removed prior to application of transdermal delivery system to the skin.
  • Protective liner or release liner known to those skilled in the art includes such as but not limited to polyester film, siliconized polyester films, siliconized polyethylene terephthalate film, fluoropolymer coated polyester film, etc.
  • protective liner or release liner includes such as 3M SCOTCHPAKTM 1022 release liner fluoropolymer coated polyester Film, 3M SCOTCHPAKTM 9741 release liner fluoropolymer coated polypropylene film, 3M SCOTCHPAKTM 9742 release liner fluoropolymer coated polyester film, 3M SCOTCHPAKTM 9744 release liner fluoropolymer coated polyester film, 3M SCOTCHPAKTM 9755 release liner fluoropolymer coated polyester film, 3M SCOTCHPAKTM 1022W release liner fluoropolymer coated polyester film - white, 3M SCOTCHPAKTM 9755W release liner fluoropolymer coated polyester film - white, 3MTM SCOTCHPAKTM 9709 release liner fluorosilicone coated polyester film, etc.
  • protective liner other protective liners which are well known to those skilled in the art also within the scope of this patent application.
  • tapes can also be used in the transdermal delivery systems.
  • tapes well known in the art includes such as 3M CoTranTM 9695 nonwoven polyester tape, 3M CoTranTM 9698 nonwoven polyurethane tape, 3M CoTranTM 9766 double coated polyethylene tape, 3M CoTranTM 9722L polyvinyl chloride foam tape, 3M CoTranTM 9773 polyethylene foam tape, etc.
  • transdermal gel formulation of the invention can be applied topically to the skin.
  • transdermal gel formulation of the invention can be incorporated into a reservoir patch, wherein reservoir patch can be applied to the skin.
  • period of topical application of transdermal gel formulation of the invention can be for up to one day.
  • period of topical application of reservoir patch comprising transdermal gel formulation of the invention can be selected from the group such as for one day, for two days, for three days, for four days, for five days, for six days, for seven days or more thereby reducing the dosing frequency.
  • transdermal gel formulation or reservoir patch to the skin of the patient based on the factors like type, severity and symptoms of allergic rhinitis and/or urticaria such as perennial allergic rhinitis, seasonal allergic rhinitis, chronic idiopathic urticaria, acute urticaria, etc.
  • Cetirizine dihydrochloride is an antihistamine. It has potential to treat and/or prevent and/or alleviate symptoms associated with allergies, treat and/or prevent and/or alleviate symptoms associated with upper respiratory allergy, treat and/or prevent and/or alleviate symptoms and/or symptoms of diseases caused by extra release of histamines in the body.
  • Those skilled in the art can choose the period of application of transdermal gel formulation or reservoir patch (comprising transdermal gel formulation) to the skin to treat and/or prevent and/or alleviate symptoms of allergies, treat and/or prevent and/or alleviate symptoms of upper respiratory allergy, treat and/or prevent and/or alleviate symptoms and/or symptoms of diseases caused by extra release of histamines in the body.
  • Period of continuous patch application can be selected from the group comprising one day, two days, three days, four days, five days, six days, seven days, or more.
  • formulation of the invention can transdermally deliver cetirizine dihydrochloride continuously for 7 days.
  • formulation of the invention may have the potential to transdermally deliver therapeutically effective amount of cetirizine dihydrochloride to treat and/or prevent and/or relief of the symptoms of allergic rhinitis and/or urticaria by applying formulation of the invention on the appropriate surface area of the skin and/or by applying transdermal reservoir patch of appropriate surface area containing transdermal gel formulation of the invention to the skin wherein, duration of the application of formulation can be for up to one day, duration of topical application of reservoir patch can be selected from the group such as for one day, for two days, for three days, for four days, for five days, for six days, for seven days.
  • flux of the formulation can be altered by changing the parameters without any limitation such as surface area of the patch, cetirizine dihydrochloride concentration, composition of the carrier system, pH of the formulation, type and/or concentration of penetration enhancers and/or solvents and/or gelling agents, etc. without departing from the teachings of present invention.
  • cetirizine dihydrochloride concentration concentration of the carrier system
  • pH of the formulation pH of the formulation
  • penetration enhancers and/or solvents and/or gelling agents etc.
  • Topical application of reservoir patch to skin for more than 7 days is also within the scope of this patent application.
  • transdermal gel formulation has continuous in vitro transdermal delivery of cetirizine dihydrochloride for a period of 7 days. Therefore, dosing frequency of cetirizine dihydrochloride for the treatment and/or prevention and/or relief of symptoms associated with allergic rhinitis and/or urticaria and/or upper respiratory allergies can be reduced by continuous topical application of reservoir patch wherein duration of topical application is selected from the group comprising for one day, two days, three days, four days, five days, six days, seven days.
  • Lubrizol listing of Lubrizol polymers www.lubrizol.com/en/Life- Sciences/Regulatory/USP-NF-Listing-of-Lubrizol-Polymers accessed on Aug 30, 2017

Abstract

La présente invention concerne une formulation semi-solide transdermique, de préférence une formulation de gel transdermique comprenant du dichlorhydrate de cétirizine et un système de véhicule comprenant des excipients tels que, mais non limités à, des solvants, des agents de pénétration, des agents gélifiants ou des polymères, des agents d'ajustement du pH, seuls ou dans des combinaisons de ceux-ci. La formulation de gel transdermique permet une administration continue in vitro de dichlorhydrate de cétirizine pendant une durée allant jusqu'à sept jours. La formulation de gel transdermique peut être ajoutée à un patch de réservoir. Pour le traitement et/ou la prévention et/ou le soulagement de symptômes associés à la rhinite allergique et/ou à l'urticaire et/ou aux allergies respiratoires supérieures, par application topique d'une formulation de gel transdermique sur la peau pendant jusqu'à un jour ou par application topique d'un patch de réservoir sur la peau pendant une durée choisie dans le groupe comprenant un jour, deux jours, trois jours, quatre jours, cinq jours, six jours ou sept jours, en réduisant la fréquence d'administration.
PCT/US2017/052408 2016-09-30 2017-09-20 Systèmes d'administration transdermique et/ou topique comprenant du dichlorhydrate de cétirizine WO2018063876A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402037P 2016-09-30 2016-09-30
US62/402,037 2016-09-30

Publications (1)

Publication Number Publication Date
WO2018063876A1 true WO2018063876A1 (fr) 2018-04-05

Family

ID=61760112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/052408 WO2018063876A1 (fr) 2016-09-30 2017-09-20 Systèmes d'administration transdermique et/ou topique comprenant du dichlorhydrate de cétirizine

Country Status (1)

Country Link
WO (1) WO2018063876A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886843A (zh) * 2022-05-26 2022-08-12 中国人民解放军南部战区总医院 一种用于治疗雄激素性脱发的盐酸西替利嗪脂质体凝胶及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000168A1 (fr) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Composition topique contenant une combinaison de composes antihistaminiques et de composes terpenoides
WO1998018416A1 (fr) * 1996-10-30 1998-05-07 Theratech, Inc. Esters d'acide gras d'acide glycolique et ses sels, utilises comme renforcateurs de penetration
US20030147926A1 (en) * 2000-04-26 2003-08-07 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US6790847B2 (en) * 2002-01-04 2004-09-14 Oramon Arzneimittel Gmbh Topical application of cetirizine and loratadine
US20150374703A1 (en) * 2011-11-23 2015-12-31 Michael Leighton Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
US20160114041A1 (en) * 2013-01-31 2016-04-28 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000168A1 (fr) * 1996-07-02 1998-01-08 Novartis Consumer Health S.A. Composition topique contenant une combinaison de composes antihistaminiques et de composes terpenoides
WO1998018416A1 (fr) * 1996-10-30 1998-05-07 Theratech, Inc. Esters d'acide gras d'acide glycolique et ses sels, utilises comme renforcateurs de penetration
US20030147926A1 (en) * 2000-04-26 2003-08-07 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US6790847B2 (en) * 2002-01-04 2004-09-14 Oramon Arzneimittel Gmbh Topical application of cetirizine and loratadine
US20150374703A1 (en) * 2011-11-23 2015-12-31 Michael Leighton Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
US20160114041A1 (en) * 2013-01-31 2016-04-28 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANTASART, D ET AL.: "Structure Enhancement Relationship of Chemical Penetration Enhancers in Drug Transport across the Stratum Corneum", PHARMACEUTICS, vol. 4, 2012, pages 71 - 92, XP055498233 *
CIURLIZZA C ET AL.: "Semisolid Formulations containing Cetirizine: Human Skin Permeation and Topical Antihistaminic Evaluation in a Rabbit Model", ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 306, no. 8, 2014, pages 711 - 717, XP035393488 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886843A (zh) * 2022-05-26 2022-08-12 中国人民解放军南部战区总医院 一种用于治疗雄激素性脱发的盐酸西替利嗪脂质体凝胶及其制备方法和应用
CN114886843B (zh) * 2022-05-26 2023-08-11 中国人民解放军南部战区总医院 一种用于治疗雄激素性脱发的盐酸西替利嗪脂质体凝胶及其制备方法和应用

Similar Documents

Publication Publication Date Title
US10758502B2 (en) High concentration local anesthetic formulations
US20070117828A1 (en) Pharmaceutical compositions
CZ20023030A3 (cs) Farmaceutický prostředek
JP2019534288A (ja) デクスメデトミジン経皮送達デバイスを用いた疼痛管理の方法
RU2759726C2 (ru) Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак
US20180250281A1 (en) Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride
MX2015004747A (es) Un metodo veterinario de aliviar la aversion al ruido.
WO2018063876A1 (fr) Systèmes d'administration transdermique et/ou topique comprenant du dichlorhydrate de cétirizine
AU2012335803B2 (en) Pharmaceutical compositions comprising 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US20160151349A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US11571421B2 (en) GABAA positive allosteric modulator compounds for treatment of itch and/or dermatitis
Sharma et al. Penetration enhancers in current perspective
AU2021260149A1 (en) Oral delivery system comprising hydroxychloroquine and/or chloroquine
WO2001087236A2 (fr) Administration topique de compositions pharmacologiques dans le traitement non systemique du prurit
CA3165449A1 (fr) Cyclosporine topique pour le traitement du psoriasis et d'autres maladies
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂
JP6526475B2 (ja) 経皮唾液腺投与用の唾液分泌促進剤
US20230123388A1 (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
KR20230026449A (ko) (1s)-1-페닐-2-피리딘-2-일레탄아민의 국소 제형
CN117479930A (zh) 用于治疗癫痫发作病症的药物组合物和方法
Kitzmiller et al. Multiple-application pharmacokinetics and adhesion analyses of a buprenorphine transdermal system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17857213

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17857213

Country of ref document: EP

Kind code of ref document: A1